Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Niessner

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Experimental Dermatology|April 20, 2017
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1Heike Niessner, Corinna Kosnopfel, Tobias Sinnberg, et al.
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
Molecules (Basel, Switzerland)|September 28, 2021
Comparative Analysis of the Antitumor Activity of Cis- and Trans-Resveratrol in Human Cancer Cells with Different p53 StatusChristian Leischner, Markus Burkard, Anja Michel, et al.
Molecular Cancer|February 19, 2018
Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotypeTobias Sinnberg, Mitchell P Levesque, Jelena Krochmann, et al.
Cells|January 21, 2023
High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant MelanomaMarkus Burkard, Heike Niessner, Christian Leischner, et al.
The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Cancers|August 23, 2020
Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and InvasionCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|January 22, 2026
Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological EffectAxel Erich Theuer, Nicolas Schierbaum, Heike Niessner, et al.
Frontiers in Oncology|September 10, 2014
Epigenetic impacts of ascorbate on human metastatic melanoma cellsSascha Venturelli, Tobias W Sinnberg, Alexander Berger, et al.
Cells|April 12, 2022
Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In VivoHeike Niessner, Markus Burkard, Christian Leischner, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Experimental Dermatology|April 20, 2017
Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1Heike Niessner, Corinna Kosnopfel, Tobias Sinnberg, et al.
Neuro-Oncology Advances|December 11, 2020
An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER studyTeresa Amaral, Heike Niessner, Tobias Sinnberg, et al.
Molecules (Basel, Switzerland)|September 28, 2021
Comparative Analysis of the Antitumor Activity of Cis- and Trans-Resveratrol in Human Cancer Cells with Different p53 StatusChristian Leischner, Markus Burkard, Anja Michel, et al.
Molecular Cancer|February 19, 2018
Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotypeTobias Sinnberg, Mitchell P Levesque, Jelena Krochmann, et al.
Cells|January 21, 2023
High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant MelanomaMarkus Burkard, Heike Niessner, Christian Leischner, et al.
The Journal of Investigative Dermatology|December 17, 2008
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomideTobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner, et al.
Cancers|August 23, 2020
Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and InvasionCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|January 22, 2026
Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological EffectAxel Erich Theuer, Nicolas Schierbaum, Heike Niessner, et al.
Frontiers in Oncology|September 10, 2014
Epigenetic impacts of ascorbate on human metastatic melanoma cellsSascha Venturelli, Tobias W Sinnberg, Alexander Berger, et al.
Cells|April 12, 2022
Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In VivoHeike Niessner, Markus Burkard, Christian Leischner, et al.
Pageof 6